Organovo Holdings (ONVO) : 2 analysts are covering Organovo Holdings (ONVO) and their average rating on the stock is 1, which is read as a Strong Buy. 2 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 4, which recommends a Sell affirms that they expect a large upside in the stock from the current levels.
Organovo Holdings (ONVO) : The highest level Organovo Holdings (ONVO) is projected to reach is $5 for the short term and the lowest estimate is at $4. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $4.25 and the possibility the share price can swing is $0.35.
For the current week, the company shares have a recommendation consensus of Buy.
Organovo Holdings (NYSEMKT:ONVO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $4.25 and $4.25 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $4.40. The buying momentum continued till the end and the stock did not give up its gains. It closed at $4.40, notching a gain of 3.53% for the day. The total traded volume was 1,163,209 . The stock had closed at $4.25 on the previous day.
Organovo Holdings, Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture, and function. Its platform, NovoGen Bioprinters, is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue, which can be used for predictive preclinical testing of drug compounds.